|
Dobbs 2006 [26]
|
Retrospective nonrandomized controlled trial
|
USA
|
ASR + PSF vs PSF
|
20/34
|
2.4
| ① |
|
Zhang 2012 [52]
|
Prospective nonrandomized controlled trial
|
China
|
ASR + PSF vs PSF
|
31/33
|
2
| ①, ④ |
|
Zhang 2009 [41]
|
Retrospective nonrandomized controlled trial
|
China
|
ASR + PSF vs PSF
|
32/94
|
3.4
| ① |
|
Qiu 2011 [42]
|
Retrospective nonrandomized controlled trial
|
China
|
VAT+PSF vs PSF
|
18/27
|
3.65
| ①, ④ |
|
Zhang 2011 [51]
|
Retrospective nonrandomized controlled trial
|
China
|
ASR + PSF vs PSF
|
12/17
|
3
| ① |
|
Kim 2005 [34]
|
Prospective nonrandomized controlled trial
|
USA
|
PSF vs WT vs ASF vs ASR + PSF
|
49/41/16/12
|
5
| ① |
|
Bullmann 2013 [46]
|
Prospective nonrandomized controlled trial
|
Germany
|
ASF vs WT
|
40/29
|
2
| ①, ③, ④ |
|
Vedantam 2000 [44]
|
Prospective nonrandomized controlled trial
|
USA
|
PSF vs WT vs ASF vs ASR + PSF
|
47/33/7/11
|
2
| ①, ②, ③ |
|
Kim 2008 [33]
|
Retrospective nonrandomized controlled trial
|
USA
|
WT vs ASF
|
35/29
|
2
| ②, ③ |
|
Faro 2005 [28]
|
Prospective nonrandomized controlled trial
|
USA
|
VAT vs ASF
|
31/23
|
1
| ①, ②, ③ |
|
Kishan 2007 [35]
|
Prospective nonrandomized controlled trial
|
USA
|
VAT vs WT
|
36/43
|
2
| ②, ③ |
|
Lenke 2004 [15]
|
Prospective nonrandomized controlled trial
|
USA
|
VAT+PSF vs ASR + PSF
|
21/16
|
2
| ①, ②, ③ |
|
Verma 2011 [45]
|
Retrospective nonrandomized controlled trial
|
USA
|
PSF vs ASF vs VAT vs VAT+PSF
|
70/35/32/22
|
2
| ②, ③, ④ |
|
Zhou 2011 [49]
|
Retrospective nonrandomized controlled trial
|
China
|
PSF vs WT
|
24/20
|
2
| ①, ②, ③, ④ |
|
Greggi 2010 [31]
|
Retrospective nonrandomized controlled trial
|
Italy
|
WT vs PSF
|
40/40
|
5
| ①, ②, ③, ④ |
|
Lonner 2009 [37]
|
Retrospective nonrandomized controlled trial
|
USA
|
VAT vs PSF
|
17/17
|
2
| ④ |
|
Newton 2013 [40]
|
Prospective nonrandomized controlled trial
|
USA
|
VAT vs ASF vs PSF
|
55/17/77
|
2
| ②, ③, ④ |
|
Suk 2008 [43]
|
Retrospective nonrandomized controlled trial
|
Korea
|
PSF vs WT
|
37/20
|
2
| ①, ②, ③, ④ |
|
Graham 2000 [30]
|
Prospective nonrandomized controlled trial
|
USA
|
WT vs ASF
|
31/20
|
2
| ②, ③ |
|
Miljenko 2006 [29]
|
Prospective nonrandomized controlled trial
|
Croatia
|
ASF vs PSF
|
25/25
|
2
| ① |
|
Lenke 1999 [36]
|
Prospective nonrandomized controlled trial
|
USA
|
ASF vs PSF
|
70/53
|
2
| ① |
|
Wong 2004 [48]
|
Retrospective nonrandomized controlled trial
|
Singapore
|
PSF vs VAT
|
19/12
|
2
| ④ |
|
Muschik 2006 [39]
|
Retrospective nonrandomized controlled trial
|
Germany
|
ASF vs PSF
|
37/104
|
2
| ①, ④ |
|
Lonner 2006 [38]
|
Retrospective nonrandomized controlled trial
|
USA
|
VAT vs PSF
|
28/23
|
2
| ④ |
|
Hee 2007 [32]
|
Retrospective nonrandomized controlled trial
|
Singapore
|
ASF vs PSF
|
25/11
|
3.7
| ① |
|
Wang 2008 [47]
|
Prospective nonrandomized controlled trial
|
China
|
ASF vs PSF
|
16/16
|
2
| ① |
|
Dong 2015 [27]
|
Retrospective nonrandomized controlled trial
|
China
|
ASF vs PSF
|
17/36
|
2
| ①, ④ |
|
Zhan 2010 [50]
|
Retrospective nonrandomized controlled trial
|
China
|
ASF vs PSF
|
22/20
|
2
| ①, ④ |
